The HRV Pharma Phatebo acquisition was announced on 3 November 2026: Hyderabad-based HRV Pharma has signed definitive agreements to buy 100% of Phatebo GmbH, a company in Hilzingen, Germany, from ZeroStack Corp. The price has not been disclosed and no closing date has been given. HRV’s chief executive, Hari Kiran Chereddi, said the deal gives the company its first finished formulations business. A nuance matters, though: Phatebo does not manufacture medicines but sources and distributes comparator, investigational and ancillary medicines for clinical trials. This explainer sets out what is known, what the deal changes and what is still unclear.
Key takeaways on the HRV Pharma Phatebo acquisition
- HRV Pharma has signed definitive agreements to acquire 100% of Phatebo GmbH from ZeroStack Corp.
- The price and the expected closing date have not been disclosed.
- Phatebo, founded in 2015 and based in Hilzingen, Germany, had revenue of about ₹350 crore in 2025.
- It sources comparator, investigational and ancillary medicines for clinical trials and holds a German pharmaceutical wholesale authorisation.
- Managing Director Martin Lisker and his team stay; Phatebo keeps its name and existing customer agreements continue.
- HRV, an API-focused company, calls the deal its first finished formulations business.
Who are the two companies?
HRV Pharma, founded in 2015 and based in Hyderabad, describes itself as an asset-light, intellectual-property-led company focused on active pharmaceutical ingredients. It has offices in India, the United States, the Netherlands, Dubai, Mexico and Turkey, works with more than 50 manufacturing partners that hold US FDA or EU-GMP approvals, and has customers in 55 countries. Phatebo, also founded in 2015, supplies global pharmaceutical companies and contract research organisations with the medicines they need to run clinical trials.
What does Phatebo actually do?
Clinical trials often need products beyond the experimental drug itself. A comparator is an existing medicine used as the standard of care against which a new drug is tested. Ancillary medicines are supportive products used during a trial. Sourcing these in the right quantities, with the right packaging and documentation, across many countries, is a specialised logistics and regulatory task. Phatebo says it works under good distribution practice, or GDP, the quality standard for storing and moving medicines, and holds a German wholesale authorisation. The German federal institute for drugs and medical devices, BfArM and the European Medicines Agency publish information on the European regulatory framework.
Why clinical trials need a supply specialist
Running a trial across several countries means that every site needs the right product, in the right quantity, at the right time, with paperwork that satisfies each country’s regulator. A shortage at one site can delay enrolment, and a labelling or storage error can compromise data. Sponsors, the companies funding trials, therefore often hand sourcing to specialists that know which markets carry which comparator products and how to move them legally and safely. This is a services business: revenue depends on winning contracts with sponsors and contract research organisations, and on a reputation for reliability, more than on owning factories.
Why “finished formulations” needs a footnote
HRV has called Phatebo its first finished formulations business. Finished formulations are ready-to-use medicines such as tablets and injections, as opposed to the active ingredients HRV has traditionally supplied. Phatebo, however, is a sourcing and distribution business for trial supplies, not a manufacturer of finished products. The description is therefore accurate in the sense that Phatebo handles finished medicines, but it does not mean HRV is entering formulation manufacturing. The announcement does not say whether HRV plans to develop such manufacturing later.
The deal at a glance
| Item | Detail |
|---|---|
| Buyer | HRV Pharma, Hyderabad, India |
| Target | Phatebo GmbH, Hilzingen, Germany |
| Seller | ZeroStack Corp. |
| Stake | 100% |
| Price | Not disclosed |
| Closing date | Not disclosed |
| Target revenue | About ₹350 crore in 2025 |
| Management | Martin Lisker and team continue |
How to read an acquisition with no price
When a price is not disclosed, readers cannot judge value, so attention shifts to other signals. Does management stay, as it does here? Does the target keep its brand and customer contracts, as the company says it will? Is the target’s revenue large relative to the buyer, which the available material does not allow us to say because HRV’s own revenue was not given? And what conditions must be met before closing? Until the parties disclose more, the sensible reading is that this is a strategic step of uncertain financial size, and that claims about its effect on earnings would be speculation.
Timeline
- 2015: HRV Pharma and Phatebo are both founded.
- 2025: Phatebo reports revenue of about ₹350 crore.
- 3 November 2026: definitive agreements announced.
- To be announced: closing and integration plans.
Market context: active pharmaceutical ingredients
According to Acumen Research And Consulting, the global active pharmaceutical ingredient market was USD 255.47 billion in 2025 and is projected to reach USD 473.20 billion by 2035, a compound annual growth rate of 6.3% for 2026 to 2035. North America held over 39% in 2025, Asia-Pacific about 25% with the fastest growth at 8.5%, and Europe about 22%. By our calculation the endpoints imply about 6.4%, close to the stated rate. The page header says the forecast runs to 2036 while the title says 2035, and it was updated in June 2026. These figures describe HRV’s traditional ingredient market, not clinical-trial supply, which the report does not cover.
Our analysis
In our assessment, the deal gives an ingredient-focused company a foothold in Europe and in the clinical-trial supply chain, which is a different business with different customers, margins and regulatory demands. That may diversify revenue, but it also adds integration and compliance work. The announcement does not give a price, financing or expected synergies, so the financial logic cannot be assessed.
What is not disclosed
- The purchase price and how it will be funded.
- Expected closing date and any conditions or approvals.
- Phatebo’s profitability.
- Plans for any manufacturing of finished formulations.
Risks and caveats
- The deal is signed but not yet closed.
- GDP compliance, integration and trade and logistics are the main operational risks.
- Revenue figures are company-reported.
- This article is news reporting and not investment advice.
What to watch next
- Closing of the transaction.
- Disclosure of price and financing.
- Customer and product developments at Phatebo.
- Any move by HRV into formulation manufacturing.
General background
For related coverage, see our report on a recent pharmaceutical deal in Europe, and browse the Pharmaceutical section.
Questions readers are asking about the HRV Pharma Phatebo acquisition
How much is HRV paying for Phatebo?
The price has not been disclosed.
Is Phatebo a manufacturer?
No. It sources and distributes medicines for clinical trials.
When will the deal close?
No closing date has been given.
FAQ
What is a comparator drug?
An existing treatment used as the standard against which a new drug is tested.
What is GDP?
Good distribution practice, the quality standard for storing and moving medicines.
What is an API?
An active pharmaceutical ingredient, the component of a medicine that has the therapeutic effect.
How we reported this: details come from the HRV Pharma announcement of 3 November 2026 as reported in trade and business press; market figures are attributed to Acumen Research And Consulting; calculations marked as ours are our own. Last updated 5 November 2026. This is news reporting and not investment advice.
